Neuphoria Therapeutics (NEUP) Shares Outstanding (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Shares Outstanding (Entity) of $30062.0 for Q1 2026, up 214.79% year-over-year from $9550.0 in Q1 2025, and up 19.29% quarter-over-quarter from $25201.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Shares Outstanding (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Shares Outstanding (Entity) for 7 consecutive years, with $30062.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 214.79% year-over-year to $30062.0; the TTM figure through Mar 2026 stood at $30062.0 (up 214.79% YoY), while the FY2025 annual figure was $9016.0, down 98.92% from the prior year.
- Shares Outstanding (Entity) improved to $30062.0 in Q1 2026 per NEUP's latest filing, from $25201.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $1.3 million in Q3 2024 and bottomed at $4763.0 in Q4 2023.
- Historically, Shares Outstanding (Entity) has averaged $325885.2 across 5 years, with a median of $25201.0 in 2025.
- Annual changes were most pronounced in 2025 — Shares Outstanding (Entity) tumbled 99.04% — and 2026, when it jumped 214.79%.
- Neuphoria Therapeutics' Shares Outstanding (Entity) stood at $626526.0 in 2022, then plunged by 99.24% to $4763.0 in 2023, then jumped by 83.73% to $8751.0 in 2024, then jumped by 187.98% to $25201.0 in 2025, then increased by 19.29% to $30062.0 in 2026.
- Business Quant data shows NEUP's Shares Outstanding (Entity) at $30062.0 in Q1 2026, $25201.0 in Q4 2025, and $12478.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 5.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.41 Mn |
| Dec 31, 2025 | 4.54 Mn |
| Sep 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.72 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Sep 30, 2024 | 234.00 Mn |
| Jun 30, 2024 | 149.79 Mn |
| Mar 31, 2024 | 981,040.00 |
| Dec 31, 2023 | 857,264.00 |
| Sep 30, 2023 | 124.66 Mn |
| Jun 30, 2023 | 122.39 Mn |
| Jun 30, 2022 | 112.77 Mn |
| Jun 30, 2021 | 64.99 Mn |
| Jun 30, 2020 | 45.40 Mn |